Walleye Capital
INZY

Walleye Capital’s Inozyme Pharma INZY Stock Holding History

Walleye Capital’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-74,375
Closed -$67.7K – 4748
2025
Q1 		$67.7K Sell
74,375
-163,245
-69% -$226K ﹤0.01% 3764
2024
Q4 		$658K Buy
+237,620
New +$904K ﹤0.01% 2750
2023
Q4 		– Sell
-35,058
Closed -$147K – 5207
2023
Q3 		$147K Sell
35,058
-206,013
-85% -$1.05M ﹤0.01% 3746
2023
Q2 		$1.34M Buy
+241,071
New +$1.42M ﹤0.01% 1606
2022
Q4 		– Sell
-117,529
Closed -$315K – 3396
2022
Q3 		$315K Buy
117,529
+16,087
+16% +$58.2K 0.01% 1805
2022
Q2 		$484K Buy
+101,442
New +$441K 0.01% 1050
2022
Q1 		– Sell
-15,588
Closed -$106K – 2426
2021
Q4 		$106K Buy
+15,588
New +$135K ﹤0.01% 1666

Other funds holding INZY

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Walleye Capital's INZY Position: Q2 2025 in Review

Walleye Capital sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 74,375 shares — an estimated $67.7K sold.

Walleye Capital first reported a position in INZY in Q4 2021 and held it in 7 quarters. The position peaked at $1.34M in Q2 2023. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

  • Walleye Capital reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
  • Walleye Capital sold 74,375 Inozyme Pharma shares in Q2 2025, an estimated $67.7K.
  • Walleye Capital first reported a position in Inozyme Pharma in Q4 2021 and held it in 7 quarters.
  • Walleye Capital's Inozyme Pharma position peaked at $1.34M in Q2 2023.
  • 86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on Walleye Capital's 13F filing for Q2 2025, filed 13 Aug 2025.